What Does It Take to Create a Safe and Effective Vaccine? A Virtual Conversation with Dr. Amit Kumar, Anixa Biosciences
Tuesday, December 8 at 7 pm EST on Zoom
- How do you create a safe and effective vaccine?
- When do you know when it is ready for the public?
- What do interim results tell us? And what don’t they tell us?
- How many people need to be vaccinated to know if a vaccine is effective?
Science Writers in New York invites you to join us for a conversation with Dr. Amit Kumar, chairman, president, and chief executive officer of Anixa Biosciences, a biotechnology company developing several programs addressing cancer and infectious disease.
Anixa’s vaccine portfolio consists of a technology to prevent triple-negative breast cancer (TNBC), the most lethal form of breast cancer, a vaccine against ovarian cancer (in collaboration with the Cleveland Clinic) as well as newly designed drugs that are purposefully developed to specifically target SARS-CoV-2 for the treatment of COVID-19.
Dr. Kumar will talk to SWINY co-chair David Levine (@dlloydlevine) about his company’s vaccines for cancer (both breast and ovarian) and its treatments for COVID-19. He will also explain the science behind the vaccines by Pfizer and Moderna, both of which messenger RNA vaccines, which have never been used in past vaccines, and discuss the interim results.
Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002 to 2008. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a postdoctoral fellowship at Harvard.
Anixa is a publicly traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a COVID-19 therapeutics program focused on inhibiting certain viral protein function. The company’s vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple-negative breast cancer (TNBC), the deadliest form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Do you have a question for Dr. Kumar you would like answered? Submit it here.
Tuesday, December 8
7 to 8 pm EST